Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB4A | P04350 | 3/20 | 0.51 |
| ▸ | TUBB | P07437 | 3/20 | 0.51 |
| ▸ | TUBA3C | P0DPH7 | 3/20 | 0.51 |
| ▸ | TUBA1B | P68363 | 3/20 | 0.51 |
| ▸ | TUBA4A | P68366 | 3/20 | 0.51 |
| ▸ | TUBB4B | P68371 | 3/20 | 0.51 |
| ▸ | TUBB3 | Q13509 | 3/20 | 0.51 |
| ▸ | TUBB2A | Q13885 | 3/20 | 0.51 |
| ▸ | TUBB8 | Q3ZCM7 | 3/20 | 0.51 |
| ▸ | TUBA3E | Q6PEY2 | 3/20 | 0.51 |
| ▸ | TUBA1A | Q71U36 | 3/20 | 0.51 |
| ▸ | TUBA1C | Q9BQE3 | 3/20 | 0.51 |
| ▸ | TUBB6 | Q9BUF5 | 3/20 | 0.51 |
| ▸ | TUBB2B | Q9BVA1 | 3/20 | 0.51 |
| ▸ | TUBB1 | Q9H4B7 | 3/20 | 0.51 |
| ▸ | NPC1 | O15118 | 4/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4629469 | 0.89 | SMN1; SMN2 (0.52) | ALDH1A1ALOX12NAMPTL3MBTL1LMNA | |
| SCHEMBL4628790 | 0.82 | NPC1 (0.72) | NPC1CYP2C19ALDH1A1CYP1A2CYP2D6 | |
| SCHEMBL4628756 | 0.81 | TP53 (0.56) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL6848908 | 0.75 | SMN1; SMN2 (0.66) | ALDH1A1KMT2ANAMPTL3MBTL1LMNA | |
| SCHEMBL4628536 | 0.75 | MALT1 (0.57) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL4629004 | 0.75 | NPC1 (0.55) | NPC1CYP2C19ALDH1A1CYP1A2CYP2D6 | |
| SCHEMBL8224616 | 0.74 | SMO (0.65) | NPC1ALDH1A1MEN1KMT2ARAB9A | |
| SCHEMBL9543614 | 0.74 | MEN1 (0.67) | CYP2C19ALDH1A1MEN1KMT2AL3MBTL1 | |
| SCHEMBL4628473 | 0.74 | MAPT (0.56) | NPC1ALDH1A1CYP1A2MEN1KMT2A | |
| SCHEMBL8815134 | 0.73 | KMT2A (0.60) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1032556-B1 | PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF USE | WYETH CORP (US) | 2007-12-19 | — | — | EP | claimed |
| US-7041702-B1 | Pharmaceutically active compounds and methods of use | SCION PHARMACEUTICALS, INC. (US) | 2006-05-09 | — | — | US | claimed |
| EP-1918272-A1 | Pharmaceutically active compounds and methods of use | Wyeth a Corporation of the State of Delaware (US) | 2008-05-07 | — | — | EP | disclosed |
| EP-1032556-B1 | PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF USE | WYETH CORP (US) | 2007-12-19 | — | — | EP | disclosed |
| US-20060270741-A1 | Pharmaceutically active compounds and methods of use | SCION PHARMACEUTICALS, INC. (US) | 2006-11-30 | — | — | US | disclosed |
| US-7041702-B1 | Pharmaceutically active compounds and methods of use | SCION PHARMACEUTICALS, INC. (US) | 2006-05-09 | — | — | US | disclosed |
| EP-1032556-A4 | PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF USE | CAMBRIDGE NEUROSCIENCE INC (US) | 2005-02-02 | — | — | EP | disclosed |
| EP-1032556-A1 | PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF USE | CAMBRIDGE NEUROSCIENCE, INC. (US) | 2000-09-06 | — | — | EP | disclosed |
| WO-1999020599-A1 | PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF USE | CAMBRIDGE NEUROSCIENCE, INC. (US) | 1999-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060270741-A1 | Pharmaceutically active compounds and methods of use | GBA1, CTSA, GAA | TUBB4A 3228/4885TUBB 2626/4885TUBA3C 1614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.